The extent of surgical therapy of urological tumors and the intensity of post-surgical or primary chemo- or radiotherapy are dependent on staging and grading. Since the proliferative activity determines the size of the tumor, the primary prognostic evaluation corresponds with the grading. The histologic, cytologic, immunohistochemical and cell kinetic methods of examinating urological tumors are discussed considering their significance. Two tumor subgroups of malignancy are differentiated, one with a low risk and one with a high risk. The tumor group of intermediate malignancy (GII) consists of a mixture of both prognostic groups. Possibilities of an easy-to-use subgrading are given in order to differentiate a particular group from other subgroups at risk. A clear distinction between two subgroups of urologic tumors, namely with high or low malignancy, is a presupposition for the successful application of a differentiated therapy nowadays. Prognostic studies have corroborated this tumor subdivision.

Keywords:
Kidney, Urinary bladder, Prostate tumors, Grading Prognosis
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.